Latest news

  • 03 July 2017

    Sensorion Amends Existing Convertible Notes Program Under More Favorable Terms with €10 Million in Financing Read

  • 08 June 2017

    Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more